Clinical Trial Update: Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update showing results for capivasertib plus fulvestrant versus placebo plus fulvestrant in locally advanced (inoperable) or metastatic HR+/HER2- …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capivasertib (capivasertib)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-10-27